Please assess the completion status of the following clinical trial:

Trial Title: Effect of DHA on Lipid and Carbohydrate Metabolism Alterations and Body Fat Distribution in HIV Patients Under HAART.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Serologic evidence of HIV-1.~2. Plasma triglycerides \> 2.26 mmol/L (200 mg/dL) and/or Total Cholesterol \> 6 mmol/L (232 mg/dL) measured after a fasting period of at least 12 hours and confirmed by at least two measures separated by at least an interval of one week.~3. Body mass index between 25 and 30 kg/m2.~4. Absence NSAIDs, antihypertensive drugs, lipid-lowering drugs treatments or any other medication known to affect plasma lipid levels.~5. Alcohol intake \<20 g/day.~6. Absence of Diabetes mellitus and obesity (BMI \> 30)~7. Absence of heart and liver pathologies (within 3 months prior the study).~8. Absence of renal failure (serum creatinine \> 130 mmol/L) or Cr.Cl. \< 60 ml/min /1.73 m2.~Exclusion Criteria:~1. Pregnancy or absence of adequate contraception in childbearing age women.~2. Presence or fail to fulfil one or more of the conditions listed in paragraphs 2-8 of the inclusion criteria

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DHA (Type: EXPERIMENTAL): Docosahexaenoic acid (DHA) administration to modulate Triglycerides in HIV patients under HAART
- PLACEBO (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).